Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 1021-335X Online ISSN: 1791-2431
Journal Cover
June-2016 Volume 35 Issue 6

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
June-2016 Volume 35 Issue 6

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Harmine induces cell cycle arrest and mitochondrial pathway-mediated cellular apoptosis in SW620 cells via inhibition of the Akt and ERK signaling pathways

  • Authors:
    • Jiming Liu
    • Qiang Li
    • Zhilong Liu
    • Liuming Lin
    • Xiangqiang Zhang
    • Mingrong Cao
    • Jianwei Jiang
  • View Affiliations / Copyright

    Affiliations: Department of General Surgery, First Affiliated Hospital, Jinan University, Guangzhou, Guangdong 510630, P.R. China, Department of Biochemistry, Medical College, Jinan University, Guangzhou, Guangdong 510630, P.R. China
  • Pages: 3363-3370
    |
    Published online on: March 21, 2016
       https://doi.org/10.3892/or.2016.4695
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Harmine, a β-carboline alkaloid isolated from the seeds of Peganum harmala, possesses both antitumor and anti‑nociceptive effects and inhibits human DNA topoisomerase. However, no detailed data are available concerning the mechanisms of harmine in human colorectal carcinoma SW620 cells. In the present study, we demonstrated that harmine inhibited the proliferation of SW620 cells in a dose-dependent manner using MTT and clone formation assays, and the IC50 value of harmine on the growth inhibition of SW620 cells for 48 h was 5.13 µg/ml. PI staining showed that harmine altered the cell cycle distribution by decreasing the proportion of cells in the G0-G1 phase and increasing the proportion in the S and G2-M phase. The expression level of cyclin D1 was decreased, while the expression of cyclin A, E2 and B1, CDK1/cdc2, Myt-1 and p-cdc2 (Tyr15) were increased, which was in accordance with the S and G2/M phase arrest. Hoechst 33258 staining revealed nuclear fragmentation, chromosomal condensation and cell shrinkage in the SW620 cells treated with harmine. Flow cytometry revealed that the percentage of apoptotic sub-G1 cells increased from 7.19 to 26.58%, while in the control group, sub-G1 cells only increased from 1.53 to 1.60%. Furthermore, early and late apoptotic cells were increased from 11.96 to 26.38% when incubated with the indicated concentration of harmine for 48 h, while in the control group, <8% of cells underwent apoptosis. JC-1 staining revealed that harmine decreased mitochondrial transmembrane potential (ΔΨm). The apoptosis of SW620 cells was also detected by western blot analysis, showing caspase-3 and -9, and PARP activation; the downregulation of Bcl-2, Mcl-1, Bcl-xL; and the upregulation of Bax. The expression of p-ERK, p-Akt (Ser473) and p-Akt (Thr308) was inhibited, and phosphorylation of downstream targets of Akt, such as p-FoxO3a and p-GSK‑3β were also attenuated. In conclusion, harmine induces cell cycle arrest and mitochondrial pathway-mediated cellular apoptosis in SW620 cells via inhibition of the Akt and ERK signaling pathways.

Introduction

Colon carcinoma is one of the most common and aggressive malignant tumors worldwide (1). Currently, treatments for colon carcinoma are mainly surgery and chemotherapy, but the curative effect of existing chemotherapeutic drugs is not good, and they have numerous side-effects, including myelosuppression, neutropenia and thrombocytopenia (2). Therefore, the exploration of a new approach, such as novel drugs with specific effects on colon carcinoma treatment is urgently needed.

Harmine, a β-carboline alkaloid isolated from the seeds of Peganum harmala (Fig. 1), has been traditionally used for ritual and medicinal preparations in the Middle East, Central Asia and South America (3). Previous research has shown that harmine plays roles in anticancer treatments (4–6) and possesses anti-leishmanial properties (7) and antiviral effects (8) via inhibition of DYRK1A substrate phosphorylation. This compound was also found to interfere with neuritogenesis in cultured hippocampal neurons (9) and inhibit angiogenesis (10), telomerase activity (5) and mitochondrial signaling pathways (6,11), in addition to inducing DNA single- or double-strand breaks (12). It has been reported that harmine activates both the intrinsic and extrinsic pathways of apoptosis and regulates various transcription factors and pro-inflammatory cytokines in B16F-10 cells (6). Furthermore, the in vivo anti-angiogenic activity of harmine was studied using B16F-10 melanoma cells in C57BL/6 mice. The results showed that harmine decreased tumor capillary formation and inhibited angiogenesis (4). Harmine was also shown to induce apoptosis and suppress tumor cell proliferation through the downregulation of cyclooxygenase-2 expression in gastric cancer (13). Additionally, harmine can upregulate p21 and p27, enhance the formation of complexes with the G1-S phase CDKs and cyclins, and induce G1 arrest to stall cancer progression in human breast cancer MCF7 (p53 wild-type), MCF7 (p53 knockdown) and MDA-MB-468 (p53 mutant) cells (14). In cytotoxicity assays, harmine exhibited a strong inhibitory effect on the growth and proliferation of carcinoma cells, whereas it had no significant effects on quiescent fibroblasts (15). However, no detailed data are available in regards to the growth inhibition of human colon carcinoma cells. In the present study, we investigated the effect of harmine on the growth of human SW620 cells.

Figure 1

Chemical structure of harmine.

Materials and methods

Materials

Harmine was purchased from the Xi'an Feida Bio-Tech Co., Ltd. (Xi'an, China). Fetal bovine serum (FBS), RPMI-1640 medium, trypsin and EDTA were purchased from Gibco-BRL (Gaithersburg, MD, USA); Cell Counting Kit-8 (CCK-8/WST-8 kit) was purchased from Dojindo, Japan. Dimethyl sulfoxide (DMSO), Annexin V-fluorescent isothiocyanate (FITC) and propidium iodide (PI) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Antibodies against Bax, Bcl-2, Bcl-xL, Mcl-1, caspase-9 and -3, poly(ADP-ribose) polymerase (PARP), cleaved PARP, cyclin A, B1, D1 and E2, CDK4, cdc2, p-cdc2 (Tyr15), Myt-1, Akt, p-Akt (Ser473), p-Akt (Thr308), GSK3α/β, p-GSK3β (Ser9), FoxO3a, p-FoxO3a (Ser318/321) and GAPDH as well as all secondary antibodies were purchased from Cell Signaling Technology Ltd. (Danvers, MA, USA).

Cell culture and treatment

Cells were cultured in RPMI-1640 medium supplemented with 10% FBS at 37°C in a humidified atmosphere containing 5% CO2. Harmine was dissolved in DMSO and diluted to appropriate concentrations with culture medium. The final concentration of DMSO in the culture medium did not exceed 0.1%.

CCK-8 assay

CCK-8 testing was used to monitor cell proliferation. Cells were plated at a density of 5,000 cells/well in 96-well plates. After 24 h in culture, cells were treated with harmine at the final concentrations of 0, 0.625, 1.25, 2.50, 5.00, 10.00 and 20.00 μg/ml for 48 h. Control cells were treated with DMSO. After cells were incubated with harmine for 48 h, 10 μl CCK-8 was added to each well. Absorbance was detected with an enzyme calibrator at 570 nm and then optical density (OD) values were measured. Inhibition of cell growth was computed as the percentage of viable cells compared with the control: Percentage (%) = (ODcontrol − ODtreatment)/ODcontrol × 100%. Experiments were performed in triplicate.

Clone formation assay

A clone formation assay was used to evaluate the effects of harmine on the proliferation of SW620 cells. Cells were first cultured in 12-well microplates (300 cells/well) in 2.0 ml of complete RPMI-1640 for 24 h. Then, the cells were treated with the indicated concentrations of harmine for 7 days. Finally, the cells were stained with crystal violet for 20 min. A digital camera captured images of the colonies as previously described (16).

Fluorescence microscopy assay

Harmine-induced apoptosis in SW620 cells was assessed by Hoechst 33258 staining. Following treatment with the indicated concentrations of harmine for 48 h, the cells were harvested and smeared on slides. The slides were air-dried, fixed in methanol-acetone (3:1, v/v) and stained with Hoechst 33258 (5 μg/ml) at 37°C in the dark for 20 min. Nuclear morphology was examined using fluorescence microscopy (DFC480; Leica Microsystems, Wetzlar, Germany) to identify cells undergoing apoptosis.

Flow cytometry

SW620 cells at a density of 20,000 cells/well were incubated in 6-well plates for 48 h with the indicated concentrations of harmine. After incubation, the cells were harvested, washed with phosphate-buffered solution (PBS), and fixed in 70% ice-cold ethanol overnight. Then, the fixed cells were incubated with 20 U/ml RNase I and 50 μg/ml PI for 30 min. The DNA content was determined by flow cytometry (FCM; Beckman Coulter, Fullerton, CA, USA). Apoptotic cells were identified by the sub-G1 phase in the cell cycle distribution. For assessment of the apoptotic rate, Annexin V-FITC/PI staining was performed according to the manufacturer's protocol. The cells that were Annexin V-positive and PI-negative were defined as early apoptotic cells, and cells that were both Annexin V and PI-positive were defined as late apoptotic cells. The apoptotic rate was measured by FCM (Becton-Dickinson, USA) using CellQuest software.

Membrane potential of the mitochondria (ΔΨm)

Changes in the membrane potential of mitochondria were analyzed with JC-1 staining. SW620 cells were treated with 2.50 μg/ml harmine for 48 h, and then the cells were harvested, washed with PBS, fixed in JC-1 at 37°C in the dark for 30 min, then harvested and smeared on slides. Changes in ΔΨm were measured with a fluorescence microscope according to the manufacturer's protocol.

Western blot analysis

Total protein was extracted by incubation of cell pellets with lysis buffer. The protein concentration was determined using the BCA assay (Sigma) according to the manufacturer's instructions. Cell lysates were electrophoresed on 10–15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels. The protein bands were then transferred to polyvinylidene difluoride (PVDF) membranes. After blocking with 5% dried skimmed milk, the membranes were incubated overnight at 4°C with the appropriate primary antibody. Then, the membranes were washed three times in Tris-buffered saline and Tween-20 (TBST) and incubated for 1 h at room temperature with a secondary antibody conjugated to horseradish peroxidase. After washing in TBST, the bound antibody complex was detected using an ECL chemiluminescence reagent and X-ray film (Kodak, Rochester, NY, USA).

Statistical analysis

Data were analyzed by ANOVA and Student's t-tests. These analyses were performed using SPSS 13.0 software. All results are expressed as the means ± standard error (SE) of three independent experiments. Differences with P<0.05 were considered to be statistically significant.

Results

Harmine inhibits SW620 cell proliferation

To study the effects of harmine on cell proliferation, we used a CCK-8/WST-8 assay to analyze the proliferation of the SW620 cells. After cells were incubated with the indicated concentrations of harmine for 48 h, cell viability was markedly decreased (Fig. 2A). Harmine inhibited the growth of SW620 cells in a dose-dependent manner (P<0.05 vs. control), with a half-maximal inhibitory concentration (IC50) value of 5.13 μg/ml. We further assessed the effect of harmine on the proliferation of SW620 cells using a clone formation assay. The results showed that harmine strongly inhibited SW620 cell proliferation in a dose-dependent manner after treatment with the indicated concentrations of harmine for 7 days (Fig. 2B).

Figure 2

Harmine dose-dependently decreases the cell viability in SW620 cells. (A) Effects of harmine on the cell viability of SW620 cells. The indicated concentrations of harmine were added and the cells were incubated for 48 h. Viability was measured by a CCK-8 assay. **P<0.05 vs. the control group. (B) Clone formation assay was used to evaluate the effects of harmine on the proliferation of SW620 cells. SW620 cells were treated with 0, 0.625, 1.25, 2.50 and 5.00 μg/ml harmine for 7 days and stained with crystal violet for 20 min. Results represented three independent experiments.

Harmine alters the cell cycle and modulates the expression of cell cycle regulatory proteins in SW620 cells

Flow cytometry with a PI staining assay was used to analyze the effects of harmine on the cell cycle distribution. As shown in Fig. 3A, a significant population of cells was arrested in the S phase (38.3–50.1%), compared to 38.3% in the DMSO-treated controls and the G2/M phase (9.7–20.0%), compared to 5.5% in the DMSO-treated controls after treatment with harmine at the indicated concentrations for 48 h. The population of cells in the S and G2-M phase increased, and the population of cells in the G1 phase decreased with increasing concentrations of harmine. These results indicate that cell cycle distribution was significantly arrested in the S and G2/M phases upon harmine treatment.

Figure 3

Harmine initiates cell cycle arrest in the S and G2/M phase in the SW620 cells. (A) PI staining demonstrated characteristic features of apoptosis in the harmine-exposed cells. The cell cycle distributions were detected by flow cytometry. (B) The expression of cell cycle-related proteins was analyzed by western blot analysis. The data represent one of three experiments that yielded similar results.

As significant cell cycle arrest was observed with harmine treatment, we next assessed the effect of harmine on cell cycle regulatory proteins by western blot analysis. As shown in Fig. 3B, the expression of the G1 phase-related protein as cyclin D1, was significantly reduced after treatment with harmine for 48 h. However, the expression levels of S- and G2/M phase-related proteins, such as cyclin A, B1 and E2, increased, and those of G2/M phase-related proteins, such as cdc2, Myt-1 and p-cdc2 (Tyr15), were also increased.

Harmine induces apoptosis in SW620 cells

Apoptotic nuclear morphology was observed after Hoechst 33258 staining using fluorescence microscopy. After treatment with 5.00 μg/ml harmine for 48 h, the SW620 cells began to exhibit apoptotic characteristics, such as cell shrinkage, nuclear condensation and fragmentation. In the control group, the cells were regular in morphology, grew fully in patches and were confluent, rarely sloughing off (Fig. 4A).

Figure 4

Harmine induces SW620 cell apoptosis in dose-dependent manner. (A) Harmine-induced apoptosis in SW620 cells was assessed by Hoechst 33258 staining. Morphology of the SW620 cells exposed to harmine at different concentrations photographed under a fluorescence microscope (original magnification, ×200). (B) SW620 cells were treated with different concentrations of harmine for 48 h, and the staining of cells with Annexin V-FITC and PI was used to distinguish and quantitatively determine the percentage of apoptotic cells. (C) SW620 cells were treated with different concentrations of harmine for 48 h, and PI staining was used to detect the percentage of sub-G1 cells by flow cytometry. (D) The expression levels of apoptosis-associated proteins, caspase-9 and -3, and PARP, were analyzed by western blot analysis. The data represent one of three experiments that yielded similar results.

Apoptosis was also detected through a fluorescein Annexin V-FITC/PI double staining assay. The staining of cells with Annexin V-FITC and PI was used to distinguish and quantitatively determine the percentage of apoptotic cells. The SW620 cells underwent apoptosis after exposure to harmine at 1.25, 2.50 and 5.00 μg/ml for 48 h, and the percentage of apoptotic cells stained by Annexin V-FITC is shown in Fig. 4B. The early and late apoptotic cells increased from 11.96 to 26.38% when incubated with the indicated concentrations of harmine for 48 h, while in the control group, <8% of cells were apoptotic.

PI staining and flow cytometric assays were used to investigate the percentage of sub-G1 cells, which indicates late apoptotic cells. The SW620 cells underwent apoptosis after being exposed to harmine at 1.25, 2.50 and 5.00 μg/ml for 48 h, and the percentage of apoptotic cells as sub-G1 cells increased from 7.19 to 26.58%, while in the control group, sub-G1 cells increased from 1.53 to 1.60% (Fig. 4C). The percentage of the sub-G1 fractions increased in a dose-dependent manner.

The caspases, a family of cysteine acid proteases, are known to act as important mediators of apoptosis and can cleave various cellular substrates. To study the mechanism by which harmine induces apoptosis, western blot analysis was conducted. Exposure of the SW620 cells to harmine resulted in cleavage of caspase-3 and -9, and PARP (Fig. 4D). Increased harmine concentrations resulted in the disappearance of the intact proteins and the appearance of proteolytic cleavage bands in a concentration-dependent manner, which indicates that the cells were undergoing apoptosis.

Effect of harmine on mitochondrial membrane potential (ΔΨm) and protein expression levels of the Bcl-2 family

Loss of ΔΨm is a crucial step in the apoptotic process and is lethal to cells since it leads to the release of diverse pro-apoptotic factors, such as Smac and cytochrome c, from the mitochondria into the cytoplasm (17,18). In the present study, we used the cationic dye JC-1 to determine the status of the mitochondria in SW620 cells. In non-apoptotic cells, JC-1 enters the negatively charged mitochondria, where it aggregates and turns red. However, in cells undergoing apoptosis where the ΔΨm has collapsed, JC-1 exists as monomers in the cytosol and turns green. Our results showed that harmine induced a depletion of ΔΨm in the SW620 cells (Fig. 5A).

Figure 5

Harmine induces the apoptosis of SW620 cells through the mitochondrial signaling pathway. (A) Change in ΔΨm was evaluated by fluorescence microscopy. SW620 cells were treated with 2.50 μg/ml harmine for 48 h. (B) Harmine modulated the expression of Bcl-2 family members. SW620 cells were treated with 0, 0.625, 1.25, 2.50 and 5.00 μg/ml harmine for 48 h, and the expression of Bcl-2 family members was evaluated by western blot analysis. The data were carried out for at least three separate experiments.

Bcl-2 family proteins are key regulators of mitochondrial permeability (19). Therefore, we investigated whether the mitochondrial-mediated apoptosis in SW620 cells induced by harmine occurred as a result of the modulation of Bcl-2 family members. Harmine suppressed the expression of anti-apoptotic Bcl-2, Mcl-1 and Bcl-xL and increased the expression of pro-apoptotic Bax (Fig. 5B). As a result of these changes, the ratios of Bcl-2/Bax, Mcl-1/Bax and Bcl-xL/Bax were significantly reduced during apoptosis.

Effects of harmine on the phosphorylation of Akt and its downstream targets in SW620 cells

To explore the mechanism of cellular apoptosis induced by harmine in SW620 cells, we examined the Akt signaling pathway. The results showed that increased harmine concentrations downregulated phosphory-lation of Ser473-Akt and Thr308-Akt in a dose-dependent manner without affecting the total amount of Akt (Fig. 6). Therefore, we examined whether harmine could inhibit the phosphorylation of downstream targets of Akt. As expected, the phosphorylation levels of FoxO3a and GSK-3β were partially attenuated by harmine in a dose-dependent manner without affecting the amount of total protein in the SW620 cells. Meanwhile, the phosphorylation levels of ERK were also inhibited without affecting the amount of total protein.

Figure 6

Changes in the Akt and ERK signaling pathway. SW620 cells were treated with different concentrations of harmine for 48 h. Expression levels of the phosphorylation of ERK, Akt and phosphorylation of its downstream targets FoxO3a and GSK-3β were analyzed by western blot analysis. The data represent one of three experiments yielding similar results.

Discussion

In the present study, we demonstrated that harmine dose-dependently inhibited the growth of SW620 cells, induced mitochondrial-dependent apoptosis, and arrested the cell cycle in the S and G2/M phases. More significantly, we demonstrated that inhibition of the ERK and Akt signaling pathways was involved in the antitumor activity of harmine (Fig. 7).

Figure 7

A schematic illustration demonstrating the effects and mechanism of harmine on cell cycle distribution and apoptosis in SW620 cells. Harmine upregulates myt1, phosphorylates cdc2 at Tyr15, and inhibits the activity of the cdc2/cyclin B complex. It also demonstrates that inhibition of ERK and inhibition of PI3K/Akt signaling play important roles in harmine-induced mitochondrial associated apoptosis in SW620 cells.

The cell cycle is a common phenomenon of eukaryotic cell division. In terms of the effects on the cell cycle, there are four key checkpoints in cell cycle progression: G1/S, S, G2/M and spindle assembly checkpoints (20). Cyclin-dependent kinase inhibitors (CKIs), p53, Wee1 and Myt1 play important roles in the regulation of the cell cycle (21). At the G2/M phase checkpoint, Akt downstream proteins, Wee1 and Myt1 can inhibit the progression of the cell cycle by phosphorylating cyclin-dependent kinases (CDKs) at specific sites, such as the Tyr15 and Thr14 in the ATP binding loop of cdc2 (22,23). In these experiments, the proportions of cells in the S and G2/M phases were increased in a dose-dependent manner, as shown by flow cytometric analysis. Western blot analysis showed that harmine downregulated cyclin D1 but upregulated cyclin A, E2 and B1, in accordance with the flow cytometric analysis results. Harmine changes the cell cycle distribution, and this differs among cell types. Yang et al indicated that harmine treatment resulted in G1 cell cycle arrest in a dose-dependent manner in human breast cancer cells (14), and harmine induced human umbilical vein endothelial cells (HUVECs) to arrest at the S and G2/M phases (10). Our previous study showed that harmine also blocked the cell cycle at the S and G2/M phases in HepG2 cells, similar to our results in SW620 cells (11). Our results also showed that Myt1 and p-cdc2 (Tyr15) were upregulated, and p-Akt was downregulated following treatment with harmine. The upregulation of Myt1 reduced the activity of cdc2 through phosphorylation of Tyr15, which can induce inhibition of the cdc2/cyclin B complex and cell cycle arrest in the S and G2/M phases in SW620 cells.

Four experiments, including Hoechst 33258 staining and fluorescence microscopy; PI staining and flow cytometry; Annexin V-FITC and PI staining and flow cytometry; and western blot analysis for the detection of caspase-9 and -3 and PARP, revealed that harmine treatment resulted in SW620 cells undergoing apoptosis, and all of the results suggest that the growth inhibition of SW620 cells by harmine is due to its ability to induce apoptosis.

The Bcl-2 family proteins play important roles in the regulation of cellular apoptosis (19). When levels of anti-apoptotic proteins on the mitochondrial membrane, such as Bcl-2, Bcl-xL and Mcl-1, decrease and levels of pro-apoptotic proteins (Bax and Bak) increase or remain unchanged, the ratios of Bcl-2/Bax, Bcl-xL/Bax and Mcl-1/Bax decrease, leading to a relative increase in Bax. Bax proteins change their configurations to form oligomers and insert into the mitochondrial membrane as pores, which leads to the release of cytochrome c from the mitochondria and the initiation of the caspase cascade and subsequently to apoptosis (24,25). In our experiments, harmine caused disruption of ΔΨm and increased the expression of pro-apoptotic Bax but decreased the expression levels of anti-apoptotic Bcl-2, Bcl-xL and Mcl-1, leading to the upregulation of the ratios of Bax/Bcl-2, Bax/Bcl-xL and Bax/Mcl-1. These results demonstrated that harmine induced apoptosis through the mitochondrial pathway in SW620 cells.

The PI3K-Akt signaling pathway is an important intracellular signal transduction pathway. It plays important roles in cell proliferation, cell growth and metabolism, cell survival and angiogenesis by affecting the activity of downstream molecules, and it is closely associated with the development and progression of human tumors. This pathway can directly phosphorylate Bad on Ser136, and this creates a binding site for 14-3-3 proteins, which triggers the release of Bad from its target proteins. Akt can phosphorylate Ser196 on human pro-caspase-9, and this phosphorylation correlates with a decrease in the protease activity of caspase-9 in vitro. Akt also phosphorylates MDM2 on Ser166 and Ser186, and this promotes the translocation of MDM2 to the nucleus, where it negatively regulates p53. Other substrates of Akt include FoxO, GSK3, ASK1, TSC2, RAF1, Chk1, IKKα, p21cip1 and p27kip1, which affect cell survival and cell cycle progression (26–28). In the present study, we demonstrated that harmine inhibits Akt kinase activity by decreasing the phosphorylation of Akt on Thr308 and Ser473, and its downstream targets p-FoxO3a and p-GSK3β were markedly decreased in the presence of harmine in vitro.

The targets of FoxO transcription factors include cyclin A, cyclin B, cyclin D, cyclin E, cyclin G2; p15, p19, p21, p27, p130 (cell cycle); and Bim, BNIP3, Fas-ligand, PUMA, PTEN, TRAIL and ATG12 (apoptosis and autophagy). Phosphorylation by Akt inactivated FoxOs, resulting in its accumulation in the cytoplasm and inhibiting its transcriptional function. Through this mechanism, Akt blocks the FoxO-mediated transcription of target genes that promote apoptosis, cell cycle arrest, and metabolic processes (28). Akt also phosphorylates GSK3 isoforms at a highly conserved N-terminal regulatory site (GSK3α-Ser21 and GSK3β-Ser9), and this phosphorylation inactivates the kinase. GSK3-mediated phosphorylation of the G1 phase cyclins such as cyclin D and E, and the transcription factors c-jun and c-myc, which all play central roles in the cell cycle transition, targets them for proteasomal degradation, and GSK3 can also target and inhibit Mcl-1 (29,30). In the present study, we found that harmine inhibits the Akt signaling pathway by inhibiting the expression level of p-Akt and its downstream proteins, such as p-FoxO3 and p-GSK3β, thus inducing cell cycle arrest and mitochondrial apoptosis.

The activation of ERK1/2 has been shown to inhibit apoptosis in response to a wide range of stimuli. The activation of ERK1/2, induced by different initiating signals, results in the phosphorylation of different substrates; thus far, more than 150 substrates have been identified. ERK phosphorylates and inhibits the pro-apoptotic proteins such as caspase-8 and -9, Bad, Bim, and STAT3/5, and phosphorylates and activates anti-apoptotic proteins, such as Mcl-1, Bcl-xL, c-Flip, IEX-1, and CBP. Therefore, such as PKB/Akt, activated ERK regulates a number of cellular events, including cell proliferation and survival (31,32). In the present study, we found that harmine downregulated the expression of phosphorylated ERK and induced cell cycle arrest and mitochondrial apoptosis.

In conclusion, the present study demonstrated that harmine induced cell death and growth inhibition in human colorectal carcinoma SW620 cells. Harmine altered the cell cycle distribution by decreasing the proportion of cells in the G0–G1 phase and increasing the proportion in the S and G2-M phase, partly through upregulation of Myt-1 and p-cdc2 (Tyr15). Harmine induced mitochondrial-related cellular apoptosis by modulating the expression of Bcl-2 family proteins and decreasing mitochondrial transmembrane potential (ΔΨm). We also found that harmine decreased the levels of p-Akt and p-ERK, and this inhibition of the PI3K/Akt and ERK signaling pathways may be involved in harmine-induced cell cycle arrest and apoptosis in SW620 cells.

Acknowledgments

The present study was supported by grants from the Cultivation Fund of the First Affiliated Hospital of Jinan University (2014203), the Sci-Tech Project Foundation of Guangdong Province in China (2011B031800012), and the Natural Science Foundation of Guangdong Province in China (2014A030313356).

References

1 

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, et al: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol. 25:2198–2204. 2007. View Article : Google Scholar : PubMed/NCBI

3 

Patel K, Gadewar M, Tripathi R, Prasad SK and Patel DK: A review on medicinal importance, pharmacological activity and bioanalytical aspects of beta-carboline alkaloid ʻHarmineʼ. Asian Pac J Trop Biomed. 2:660–664. 2012. View Article : Google Scholar

4 

Hamsa TP and Kuttan G: Harmine inhibits tumour specific neo-vessel formation by regulating VEGF, MMP, TIMP and pro-inflammatory mediators both in vivo and in vitro. Eur J Pharmacol. 649:64–73. 2010. View Article : Google Scholar : PubMed/NCBI

5 

Zhao L and Wink M: The β-carboline alkaloid harmine inhibits telomerase activity of MCF-7 cells by down-regulating hTERT mRNA expression accompanied by an accelerated senescent phenotype. PeerJ. 1:e1742013. View Article : Google Scholar

6 

Hamsa TP and Kuttan G: Harmine activates intrinsic and extrinsic pathways of apoptosis in B16F-10 melanoma. Chin Med. 6:112011. View Article : Google Scholar : PubMed/NCBI

7 

Lala S, Pramanick S, Mukhopadhyay S, Bandyopadhyay S and Basu MK: Harmine: Evaluation of its antileishmanial properties in various vesicular delivery systems. J Drug Target. 12:165–175. 2004. View Article : Google Scholar : PubMed/NCBI

8 

Hudson JB, Graham EA and Towers GH: Antiviral effect of harmine, a photoactive beta-carboline alkaloid. Photochem Photobiol. 43:21–26. 1986. View Article : Google Scholar : PubMed/NCBI

9 

Göckler N, Jofre G, Papadopoulos C, Soppa U, Tejedor FJ and Becker W: Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation. FEBS J. 276:6324–6337. 2009. View Article : Google Scholar : PubMed/NCBI

10 

Dai F, Chen Y, Song Y, Huang L, Zhai D, Dong Y, Lai L, Zhang T, Li D, Pang X, et al: A natural small molecule harmine inhibits angiogenesis and suppresses tumour growth through activation of p53 in endothelial cells. PLoS One. 7:e521622012. View Article : Google Scholar

11 

Cao MR, Li Q, Liu ZL, Liu HH, Wang W, Liao XL, Pan YL and Jiang JW: Harmine induces apoptosis in HepG2 cells via mitochondrial signaling pathway. Hepatobiliary Pancreat Dis Int. 10:599–604. 2011. View Article : Google Scholar : PubMed/NCBI

12 

Boeira JM, Viana AF, Picada JN and Henriques JA: Genotoxic and recombinogenic activities of the two beta-carboline alkaloids harman and harmine in Saccharomyces cerevisiae. Mutat Res. 500:39–48. 2002. View Article : Google Scholar : PubMed/NCBI

13 

Zhang H, Sun K, Ding J, Xu H, Zhu L, Zhang K, Li X and Sun W: Harmine induces apoptosis and inhibits tumor cell proliferation, migration and invasion through down-regulation of cyclooxy-genase-2 expression in gastric cancer. Phytomedicine. 21:348–355. 2014. View Article : Google Scholar

14 

Yang X, Wang W, Qin JJ, Wang MH, Sharma H, Buolamwini JK, Wang H and Zhang R: JKA97, a novel benzylidene analog of harmine, exerts anti-cancer effects by inducing G1 arrest, apoptosis, and p53-independent up-regulation of p21. PLoS One. 7:e343032012. View Article : Google Scholar : PubMed/NCBI

15 

Song Y, Kesuma D, Wang J, Deng Y, Duan J, Wang JH and Qi RZ: Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine. Biochem Biophys Res Commun. 317:128–132. 2004. View Article : Google Scholar : PubMed/NCBI

16 

Wang W, Liao XL, Chen JH, Li DD, Lin CL, Yan YX, Tang YH and Jiang JW: Sodium valproate induces mitochondria-dependent apoptosis in human hepatoblastoma cells. Chin Med J. 124:2167–2172. 2011.PubMed/NCBI

17 

Tan ML, Ooi JP, Ismail N, Moad AI and Muhammad TS: Programmed cell death pathways and current antitumor targets. Pharm Res. 26:1547–1560. 2009. View Article : Google Scholar : PubMed/NCBI

18 

Qin S, Yang C, Li S, Xu C, Zhao Y and Ren H: Smac: Its role in apoptosis induction and use in lung cancer diagnosis and treatment. Cancer Lett. 318:9–13. 2012. View Article : Google Scholar : PubMed/NCBI

19 

Zhou F, Yang Y and Xing D: Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis. FEBS J. 278:403–413. 2011. View Article : Google Scholar

20 

Sánchez I and Dynlacht BD: New insights into cyclins, CDKs, and cell cycle control. Semin Cell Dev Biol. 16:311–321. 2005. View Article : Google Scholar : PubMed/NCBI

21 

Besson A, Dowdy SF and Roberts JM: CDK inhibitors: Cell cycle regulators and beyond. Dev Cell. 14:159–169. 2008. View Article : Google Scholar : PubMed/NCBI

22 

Berry LD and Gould KL: Regulation of Cdc2 activity by phosphorylation at T14/Y15. Prog Cell Cycle Res. 2:99–105. 1996. View Article : Google Scholar : PubMed/NCBI

23 

Fattaey A and Booher RN: Myt1: A Wee1-type kinase that phosphorylates Cdc2 on residue Thr14. Prog Cell Cycle Res. 3:233–240. 1997. View Article : Google Scholar : PubMed/NCBI

24 

Tait SW and Green DR: Mitochondria and cell death: Outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 11:621–632. 2010. View Article : Google Scholar : PubMed/NCBI

25 

Adams JM and Cory S: The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 26:1324–1337. 2007. View Article : Google Scholar : PubMed/NCBI

26 

Manning BD and Cantley LC: AKT/PKB signaling: Navigating downstream. Cell. 129:1261–1274. 2007. View Article : Google Scholar : PubMed/NCBI

27 

Faes S and Dormond O: PI3K and AKT: Unfaithful partners in cancer. Int J Mol Sci. 16:21138–21152. 2015. View Article : Google Scholar : PubMed/NCBI

28 

Zhang X, Tang N, Hadden TJ and Rishi AK: Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta. 1813:1978–1986. 2011. View Article : Google Scholar : PubMed/NCBI

29 

Luo J: Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett. 273:194–200. 2009. View Article : Google Scholar

30 

Phukan S, Babu VS, Kannoji A, Hariharan R and Balaji VN: GSK3beta: Role in therapeutic landscape and development of modulators. Br J Pharmacol. 160:1–19. 2010. View Article : Google Scholar : PubMed/NCBI

31 

Samatar AA and Poulikakos PI: Targeting RAS-ERK signalling in cancer: Promises and challenges. Nat Rev Drug Discov. 13:928–942. 2014. View Article : Google Scholar : PubMed/NCBI

32 

Peng S, Zhang Y, Zhang J, Wang H and Ren B: ERK in learning and memory: A review of recent research. Int J Mol Sci. 11:222–232. 2010. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Liu J, Li Q, Liu Z, Lin L, Zhang X, Cao M and Jiang J: Harmine induces cell cycle arrest and mitochondrial pathway-mediated cellular apoptosis in SW620 cells via inhibition of the Akt and ERK signaling pathways. Oncol Rep 35: 3363-3370, 2016.
APA
Liu, J., Li, Q., Liu, Z., Lin, L., Zhang, X., Cao, M., & Jiang, J. (2016). Harmine induces cell cycle arrest and mitochondrial pathway-mediated cellular apoptosis in SW620 cells via inhibition of the Akt and ERK signaling pathways. Oncology Reports, 35, 3363-3370. https://doi.org/10.3892/or.2016.4695
MLA
Liu, J., Li, Q., Liu, Z., Lin, L., Zhang, X., Cao, M., Jiang, J."Harmine induces cell cycle arrest and mitochondrial pathway-mediated cellular apoptosis in SW620 cells via inhibition of the Akt and ERK signaling pathways". Oncology Reports 35.6 (2016): 3363-3370.
Chicago
Liu, J., Li, Q., Liu, Z., Lin, L., Zhang, X., Cao, M., Jiang, J."Harmine induces cell cycle arrest and mitochondrial pathway-mediated cellular apoptosis in SW620 cells via inhibition of the Akt and ERK signaling pathways". Oncology Reports 35, no. 6 (2016): 3363-3370. https://doi.org/10.3892/or.2016.4695
Copy and paste a formatted citation
x
Spandidos Publications style
Liu J, Li Q, Liu Z, Lin L, Zhang X, Cao M and Jiang J: Harmine induces cell cycle arrest and mitochondrial pathway-mediated cellular apoptosis in SW620 cells via inhibition of the Akt and ERK signaling pathways. Oncol Rep 35: 3363-3370, 2016.
APA
Liu, J., Li, Q., Liu, Z., Lin, L., Zhang, X., Cao, M., & Jiang, J. (2016). Harmine induces cell cycle arrest and mitochondrial pathway-mediated cellular apoptosis in SW620 cells via inhibition of the Akt and ERK signaling pathways. Oncology Reports, 35, 3363-3370. https://doi.org/10.3892/or.2016.4695
MLA
Liu, J., Li, Q., Liu, Z., Lin, L., Zhang, X., Cao, M., Jiang, J."Harmine induces cell cycle arrest and mitochondrial pathway-mediated cellular apoptosis in SW620 cells via inhibition of the Akt and ERK signaling pathways". Oncology Reports 35.6 (2016): 3363-3370.
Chicago
Liu, J., Li, Q., Liu, Z., Lin, L., Zhang, X., Cao, M., Jiang, J."Harmine induces cell cycle arrest and mitochondrial pathway-mediated cellular apoptosis in SW620 cells via inhibition of the Akt and ERK signaling pathways". Oncology Reports 35, no. 6 (2016): 3363-3370. https://doi.org/10.3892/or.2016.4695
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team